Use of aminolevulinic and derivatives thereof

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/221 (2006.01) A61K 31/197 (2006.01) A61K 41/00 (2006.01) A61P 17/10 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2675334

The invention provides the use of a photosensitiser which is 5- aminolevulinic acid (5-ALA) or a derivative (e.g. an ester) of 5-ALA, or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises: (a) administering to said animal a composition comprising said photosensitiser; and (b) photoactivating said photosensitiser, and wherein side-effects (e.g. pain and/or erythema) of said PDT are prevented or reduced by use of one or more of (i)-(iv): (i) said composition comprises said photosensitiser in a concentration of less than 10 % wt (e.g. 0.5 to 8 %wt), (ii) said composition is administered for less than 2 hours (e.g. 30 minutes to 90 minutes) prior to said photoactivation, (iii) said photoactivation is carried out with a light source having a fluence rate of less than 50 mW/cm2(e.g. 5 to 40 mW/cm2), (iv) said photoactivation is carried out with sunlight. Preferably, side-effects of PDT are prevented or reduced by using (iii) or (iv) in combination with (i) and/or (ii).

L'invention concerne l'utilisation d'un photosensibilisateur qui est l'acide 5-aminolévulinique (5-ALA) ou un dérivé (par exemple un ester) de 5-ALA, ou un sel pharmaceutiquement acceptable de ceux-ci, dans la fabrication d'une composition destinée à être utilisée dans des procédés de thérapie photodynamique (PDT) sur un animal. Ledit PDT comprend : (a) l'administration audit animal d'une composition comprenant ledit photosensibilisateur; et (b) la photoactivation dudit photosensibilisateur. Des effets secondaires (par exemple la douleur et/ou l'érythème) de ladite PTD sont empêchés ou réduits par l'utilisation d'un ou plusieurs de (i) - (iv) : (i) ladite composition comprend ledit photosensibilisateur dans une concentration de moins de 10% en poids (par exemple 0,5 à 8% en poids), (ii) ladite composition est administrée pendant moins de 2 heures (par exemple 30 minutes à 90 minutes) avant ladite photoactivation, (iii) ladite photoactivation est effectuée avec une source de lumière ayant un taux de fluence de moins de 50 mW/cm2 (par exemple 5 à 40 mW/cm2), (iv) ladite photoactivation est effectuée avec la lumière du soleil. De préférence, les effets secondaires de la PDT sont empêchés ou réduits par l'utilisation de (iii) ou (iv) en combinaison avec (i) et/ou (ii).

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Use of aminolevulinic and derivatives thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of aminolevulinic and derivatives thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of aminolevulinic and derivatives thereof will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2069454

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.